Table 1.
General demographic and clinical data of patients
| Variables | Groups | Number of cases (%) |
|---|---|---|
| Age (years) | <50 | 21 (44) |
| ≥50 | 27 (56) | |
| Body mass index (kg/m2) | <25 | 2 (4) |
| 25–29 | 24 (50) | |
| >29 | 22 (46) | |
| Menopause status | Post | 37 (77) |
| Pre | 11 (23) | |
| Stage | I | 11 (23) |
| II | 18 (37.5) | |
| III | 16 (33) | |
| IV | 3 (6.5) | |
| Histological grade | I | 7 (14.5) |
| II | 25 (52) | |
| III | 16 (33.5) | |
| Mitotic rate | 1 | 19 (39.5) |
| 2 | 22 (46) | |
| 3 | 7 (14.5) | |
| Tumor size (cm) | <2 | 18 (37.5) |
| 2–5 | 22 (46) | |
| >5 | 8 (16.5) | |
| Lymph node involvement | Positive | 19 (39.5) |
| Negative | 29 (60.5) | |
| HER2 status | Positive | 36 (75) |
| Negative | 12 (25) | |
| ER status | Positive | 37 (77) |
| Negative | 11 (23) | |
| PR status | Positive | 35 (73) |
| Negative | 13 (27) |
Abbreviations: HER2, human epidermal growth factor receptor 2; ER, estrogen receptor; PR, progesterone receptor.